Innovent Biologics has been granted a patent for a highly stable heterodimeric bispecific antibody that can simultaneously bind to two target molecules, PD-1 and HER2. The antibody has natural IgG characteristics and is prepared using a specific method. The patent also includes specific amino acid substitutions in the Fc chains of the antibody. This bispecific antibody shows promising effects in the treatment of complex diseases. GlobalData’s report on Innovent Biologics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Innovent Biologics, Nanoparticle drug conjugates was a key innovation area identified from patents. Innovent Biologics's grant share as of September 2023 was 23%. Grant share is based on the ratio of number of grants to total number of patents.
A bispecific antibody for treating complex diseases
A recently granted patent (Publication Number: US11753471B2) describes a heterodimeric bispecific antibody that has the ability to bind to two different antigens, PD-1 and HER2. The antibody consists of two Fc chains that are linked to each other via at least one disulfide bond. The first Fc chain is linked to the PD-1 antigen-binding site, while the second Fc chain is linked to the HER2 antigen-binding site. The amino acid sequences of the immunoglobulin light chain variable region and heavy chain variable region in the PD-1 antigen-binding site are specified.
The patent also mentions that the first and second Fc chains of the bispecific antibody can have five specific amino acid substitutions, which are selected from a list of substitutions provided. These substitutions are important for the functionality of the antibody.
The bispecific antibody described in the patent is derived from immunoglobulin G (IgG) and can be composed of either Fab fragments or single-chain variable fragments (scFv). The Fab fragment can have different heavy chain variable regions and light chain variable regions.
The patent also covers compositions comprising the heterodimeric bispecific antibody and a pharmaceutically acceptable carrier. These compositions can be used for various therapeutic purposes.
Overall, this patent describes a novel heterodimeric bispecific antibody that can simultaneously bind to PD-1 and HER2 antigens. The specific amino acid substitutions and the composition of the antibody make it a potentially valuable therapeutic agent for various medical applications.
To know more about GlobalData’s detailed insights on Innovent Biologics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
